Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.41 |
| ▸ | DHODH | Q02127 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320836 | 0.87 | P2RX7 (0.42) | P2RX7KCNH2DHODHCHRM1 | |
| SCHEMBL2138302 | 0.86 | P2RX7 (0.41) | CNR2P2RX7KCNH2DHODHCHRM1 | |
| SCHEMBL589798 | 0.83 | DHODH (0.41) | DHODHTRPV1 | |
| SCHEMBL31438692 | 0.83 | DHODH (0.41) | DHODHTRPV1 | |
| SCHEMBL12911772 | 0.83 | DHODH (0.44) | DHODHLMNAHTTTRPV1TSHR | |
| SCHEMBL31231271 | 0.83 | DHODH (0.37) | CNR2CNR1P2RX7DHODHLMNA | |
| SCHEMBL22582773 | 0.83 | DHODH (0.37) | CNR2CNR1P2RX7DHODHLMNA | |
| SCHEMBL589853 | 0.82 | DHODH (0.41) | CNR1DHODHTRPV1TSHR | |
| SCHEMBL461817 | 0.82 | DHODH (0.45) | DHODHLMNAHTTTRPV1TSHR | |
| SCHEMBL12528821 | 0.81 | DHODH (0.44) | KCNH2DHODHLMNATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2093223-B1 | PROCESS AND INTERMEDIATES FOR PRODUCTION OF AN ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA (JP) | 2013-08-21 | — | — | EP | disclosed |
| US-8115006-B2 | Process for producing anthranilamide compound | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20100063293-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA ,LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-2093223-A1 | PROCESS FOR PRODUCTION OF ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2009-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063293-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | NAAA, AAAS, AADAC | CNR2 805/4885CNR1 566/4885P2RX7 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.